SBIO250117C31000
- 0.00
- 0.000.00%
Alps Etf Trust Medical Breakthroughs Etf Newsroom
Mizuho CEO Sees Global Boom in M&A After Trump Takes Office
Rhythm Gets FDA Approval for Imcivree for Toddlers
Catalyst Watch: Labor Pains for Amazon & Starbucks, Nasdaq Call-up for MicroStrategy and Pony AI Ratings
Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential
Hythm Pharmaceuticals Secures FDA Approval For Expanded Use Of IMCIVREE To Treat Obesity In Children As Young As 2 With Bardet-Biedl Syndrome Or MC4R Pathway Deficiencies, Targeting Rare Neuroendocrine Diseases
Five Reasons Why UBS Is Overweight the UK
J.P. Morgan's Top Healthcare Stocks for 2025
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
What 8 Analyst Ratings Have To Say About Avidity Biosciences
Forecasting The Future: 14 Analyst Projections For Rhythm Pharmaceuticals
PepGen Stock Craters 35% on FDA Clinical Hold
Crinetics Pharmaceuticals Analyst Ratings
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential
Stifel Upgrades Denali Therapeutics to Buy, Announces $37 Price Target
Denali Therapeutics Analyst Ratings
Morgan Stanley Upgrades PTC, Cuts Immuneering, Amicus
Xenon Pharmaceuticals Analyst Ratings
Raymond James, Cantor Bullish on UniQure Following FDA Update
Xenon New Long-Term Azetukalner Data Shows Sustained Monthly Reductions In Seizure Frequency Maintained At 85% At OLE Study Month 36; Approximately 1/3 Patients On Drug For At Least 36-Months Achieved Seizure Freedom For A Period Of 1-Year Or Longer
Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder